PROFUSA, Inc.
PFSA Healthcare Medical Devices
PROFUSA, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $100,000.00. In the quarter to June 2026, EPS grew 98.3%, free cash flow fell 359.3% and total debt fell 89.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PFSA
PROFUSA, Inc. (PFSA) P/E ratio
As of 16 October 2026, PROFUSA, Inc. (PFSA) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (June 2026) to 0.0× (February 2024); the current reading is higher than 56% of that period. That is below the Medical Devices industry median of 23.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DHAI DIH Holding US, Inc. compare | n/m |
| DYNTQ Dynatronics Corporation compare | n/m |
| MOTS Motus GI Holdings, Inc. compare | n/m |
| FEED ENvue Medical, Inc. compare | n/m |
| SSKN Strata Skin Sciences, Inc. compare | n/m |
| NUWE Nuwellis, Inc. compare | n/m |
| AFIB Acutus Medical, Inc. compare | n/m |
| THMO ThermoGenesis Holdings, Inc. compare | n/m |
| PFSA PROFUSA, Inc. | 0.0× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)